|
Diabetes Care, Vol 20, Issue 6 965-970, Copyright © 1997 by American Diabetes Association
Validity of screening for individuals at risk for type I diabetes by combined analysis of antibodies to recombinant proteins
MR Christie, U Roll, MA Payton, EC Hatfield and AG Ziegler
Department of Medicine, King's College School of Medicine, London, U.K. m.christie@kcl.ac.uk
OBJECTIVE: To determine whether screening for the presence of multiple
antibody markers for IDDM is effective at identifying individuals with high
risk for disease development. RESEARCH DESIGN AND METHODS: Antibodies to
GAD and the tyrosine phosphatase-like protein 1A-2 were determined in
sequential serum samples from 44 first-degree relatives of IDDM patients,
identified as possessing islet cell antibody (ICA) and/or insulin
autoantibody (IAA), who were followed prospectively for IDDM development,
ICA, IAA, and antibodies to GAD and 1A-2 were also determined in 93 cases
of new-onset nonfamilial IDDM. RESULTS: The presence of two or more
antibodies in addition to ICA or IAA conferred high risk (61%) for
development of IDDM within 5 years of entry into the study and identified
89% of those who have developed IDDM on current follow-up. None of the
relatives positive for ICA or IAA alone, in the absence of other antibody
markers, have developed IDDM. Antibodies to islet antigens could both
appear and disappear in follow-up samples obtained after entry into the
study. The majority (60%) of young (< 16 years), sporadic cases of IDDM
had multiple antibodies to islet antigens, but this proportion was lower in
older patients (37%). CONCLUSIONS: A screening strategy based on the
analysis of antibodies to multiple islet antigens can predict IDDM at high
sensitivity and specificity in families, and such a strategy may also be
applicable to identify young individuals in the general population with
high disease risk. Since appearance of antibodies to different antigens
occurs sequentially rather than simultaneously, accurate assessment of
diabetes risk based on the presence of multiple antibodies will require
follow-up over a number of years after the first evidence of islet
autoimmunity.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
I. Y. Jarvela, J. Juutinen, P. Koskela, A.-L. Hartikainen, P. Kulmala, M. Knip, and J. S. Tapanainen
Gestational Diabetes Identifies Women at Risk for Permanent Type 1 and Type 2 Diabetes in Fertile Age: Predictive role of autoantibodies.
Diabetes Care,
March 1, 2006;
29(3):
607 - 612.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. E. Winter, N. Harris, and D. Schatz
Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes
Clin. Diabetes,
October 1, 2002;
20(4):
183 - 191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Christie, J. Molvig, C. J. Hawkes, B. Carstensen, T. Mandrup-Poulsen, and the Canadian-European Randomised Control Trial Gro
IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin
Diabetes Care,
July 1, 2002;
25(7):
1192 - 1197.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. LaGasse, M. S. Brantley, N. J. Leech, R. E. Rowe, S. Monks, J. P. Palmer, G. T. Nepom, D. K. McCulloch, and W. A. Hagopian
Successful Prospective Prediction of Type 1 Diabetes in Schoolchildren Through Multiple Defined Autoantibodies: An 8-year follow-up of the Washington State Diabetes Prediction Study
Diabetes Care,
March 1, 2002;
25(3):
505 - 511.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Savola, E. Laara, P. Vahasalo, P. Kulmala, H. K. Akerblom, and M. Knip
Dynamic Pattern of Disease-Associated Autoantibodies in Siblings of Children With Type 1 Diabetes: A Population-Based Study
Diabetes,
November 1, 2001;
50(11):
2625 - 2632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Imagawa, T. Hanafusa, J.-i. Miyagawa, Y. Matsuzawa, and The Osaka IDDM Study Group
A Novel Subtype of Type 1 Diabetes Mellitus Characterized by a Rapid Onset and an Absence of Diabetes-Related Antibodies
N. Engl. J. Med.,
February 3, 2000;
342(5):
301 - 307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mrena, K. Savola, P. Kulmala, H. K. Åkerblom, M. Knip, and the Childhood Diabetes in Finland Study Group
Staging of Preclinical Type 1 Diabetes in Siblings of Affected Children
Pediatrics,
October 1, 1999;
104(4):
925 - 930.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. Bonifacio, V. Lampasona, and P. J. Bingley
IA-2 (Islet Cell Antigen 512) Is the Primary Target of Humoral Autoimmunity Against Type 1 Diabetes-Associated Tyrosine Phosphatase Autoantigens
J. Immunol.,
September 1, 1998;
161(5):
2648 - 2654.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1997 by the American Diabetes Association.
|
|
| |
|